2014
DOI: 10.1161/hypertensionaha.114.03173
|View full text |Cite
|
Sign up to set email alerts
|

Antenatal Corticosteroids Impact the Inflammatory Rather Than the Antiangiogenic Profile of Women With Preeclampsia

Abstract: Circulating antiangiogenic factors and proinflammatory cytokines are implicated in the pathogenesis of preeclampsia. This study was performed to test the hypothesis that steroids modify the balance of inflammatory and proangiogenic and antiangiogenic factors that potentially contribute to the patient’s evolving clinical state. Seventy singleton women, admitted for antenatal corticosteroid treatment, were enrolled prospectively. The study group consisted of 45 hypertensive women: chronic hypertension (n=6), sev… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
9
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 21 publications
(12 citation statements)
references
References 43 publications
3
9
0
Order By: Relevance
“…Despite silencing or overexpressing genes involved in the NFκB pathway in cytotrophoblasts, there was no change in sFlt-1 or sENG secretion suggesting the NFκB pathway may not be involved in their regulation. This is consistent with reports demonstrating the administration of corticosteroids, known to inhibit NFκB [37], do not change serum sFlt-1 and sENG levels in patients with preeclampsia [38]. Furthermore, silencing HO-1 did not affect the ability of sulfasalazine to reduce sFlt-1 secretion from cytotrophoblasts.…”
Section: Discussionsupporting
confidence: 92%
“…Despite silencing or overexpressing genes involved in the NFκB pathway in cytotrophoblasts, there was no change in sFlt-1 or sENG secretion suggesting the NFκB pathway may not be involved in their regulation. This is consistent with reports demonstrating the administration of corticosteroids, known to inhibit NFκB [37], do not change serum sFlt-1 and sENG levels in patients with preeclampsia [38]. Furthermore, silencing HO-1 did not affect the ability of sulfasalazine to reduce sFlt-1 secretion from cytotrophoblasts.…”
Section: Discussionsupporting
confidence: 92%
“…During admission, the majority of these patients did receive regular antihypertensive therapy and all of our patients were given steroids for fetal maturation. Antihypertensive therapy 35 and steroids 36 have not been shown to affect preeclampsia disease progression or the secretion of antiangiogenic factors. The blood pressure seemed to stabilize without the need for increasing regular antihypertensive therapy in 3 of 4 patients although there were no new symptoms and no biochemical evidence of new onset involvement of other organ systems, such as the liver and the hematological system.…”
Section: Discussionmentioning
confidence: 99%
“…In many cases the gestational age at which the samples were collected were not clearly specified. Details regarding medication during pregnancy is important as preeclamptic women, particularly in severe cases, often receive antepartum corticosteroids for fetal lung maturation during birth, which may affect protein secretion in the circulation of the mother [70]. Patients included in this analysis are of mixed background.…”
Section: Discussionmentioning
confidence: 99%